Darolutamide

Last updated

Darolutamide
ODM-201.svg
Darolutamide molecule ball.png
Clinical data
Trade names Nubeqa
Other namesDarramamide, ODM-201, BAY-1841788
AHFS/Drugs.com Monograph
MedlinePlus a619045
License data
Pregnancy
category
  • AU:X (High risk)
Routes of
administration 		By mouth
Drug class Nonsteroidal antiandrogen
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability ≤30% [4]
Protein binding Darolutamide: 92% [4]
Ketodarolutamide: 99.8% [4]
Metabolism Dehydrogenation (CYP3A4), glucuronidation (UGT1A9, UGT1A1) [4]
Metabolites Ketodarolutamide [4] [7]
Elimination half-life 16–20 hours [4] [7]
Excretion Urine: 63.4% [4]
Feces: 32.4% [4]
Identifiers
  • N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.264.885 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C19H19ClN6O2
Molar mass 398.85 g·mol−1
3D model (JSmol)
  • C[C@@H](Cn1ccc(n1)c2ccc(c(c2)Cl)C#N)NC(=O)c3cc([nH]n3)C(C)O
  • InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
  • Key:BLIJXOOIHRSQRB-PXYINDEMSA-N
   (verify)

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. [8] [4] [5] [9] [10] It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. [4] The medication is taken by mouth twice per day with food. [4]

Contents

Side effects of darolutamide added to castration may include fatigue, asthenia, pain in the arms and legs, and rash. [4] Darolutamide is a nonsteroidal antiandrogen (NSAA), and acts as a selective antagonist of the androgen receptor (AR). [4] [9] [10] It has been referred to as a second- or third-generation NSAA. [11] [12]

Darolutamide was patented in 2011 [13] and was approved for medical use in USA in July 2019, [8] [14] in the European Union in March 2020 [5] in Australia in July 2020. [15] and in Canada in 2020,

    Medical uses

    Darolutamide is approved for use concurrently with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or bilateral orchiectomy in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in men. [9] [10] It is used at a dosage of 600 mg orally twice per day (1,200 mg/day total) with food. [4] In individuals with severe renal impairment or moderate hepatic impairment, darolutamide is used at a dosage of 300 mg orally twice per day (600 mg/day total) with food. [4] No dosage adjustment is needed for mild to moderate renal impairment or mild hepatic impairment, whereas appropriate dosage adjustment for end-stage kidney disease and severe hepatic impairment is unknown. [4]

    Two 2020 meta-analyses reported that enzalutamide and apalutamide seemed to be more effective than darolutamide in improving metastasis-free survival (MFS), however 2021 matched adjusted indirect comparison showed no significant differences between drugs in terms of MFS. [16] [17] [18] According to 2021 meta-analysis darolutamide was ranked first in terms of improving overall survival (OS). [19] Also, darolutamide showed significantly lower rate of grade 3-5 adverse events (AE) compared to both enzalutamide and apalutamide. [19]

    Available forms

    Darolutamide is provided in the form of 300 mg oral film-coated tablets. [4]

    Contraindications

    Darolutamide has no contraindications in men. [4] However, the medication may have teratogenic effects in male fetuses due to its antiandrogenic effects and hence should not be used by women who are pregnant. [4]

    Side effects

    The most common side effects of darolutamide in clinical trials (≥2% incidence) in castrated men included fatigue and asthenia (16% vs. 11% for placebo), pain in extremities (6% vs. 3% for placebo), and rash (3% vs. 1% for placebo). [4] Darolutamide was also associated with higher incidences of ischemic heart disease (4.0% vs. 3.4% for placebo) and heart failure (2.1% vs. 0.9% for placebo). [4] In terms of laboratory test abnormalities, darolutamide was associated with decreased neutrophil count (20% vs. 9% for placebo), increased aspartate aminotransferase (AST) (23% vs. 14% for placebo; Grade 3–4: 0.5% vs. 0.2% for placebo), and increased bilirubin (16% vs. 7% for placebo). [4] In the clinical studies, 88% of patients treated with darolutamide were age 65 years or older. [4]

    No seizures have been observed with darolutamide in clinical trials. [7] [20] Darolutamide is an expected teratogen and has a theoretical risk of birth defects in male infants if taken by women during pregnancy. [4] It may impair male fertility. [4] When used as a monotherapy (i.e., without surgical or medical castration) in men, NSAAs are known to produce feminizing breast changes including breast tenderness and gynecomastia. [21]

    Overdose

    Darolutamide has been studied at a dosage of up to 1,800 mg/day in clinical trials. [4] There were no dose-limiting toxicities seen at this dosage. [4] Due to its saturable absorption and lack of acute toxicity, overdose of darolutamide is not expected to result in systemic toxicity in people with intact hepatic and renal function. [4] There is no specific antidote for overdose of darolutamide. [4] In the event of darolutamide overdose, if there is no toxicity, treatment can be continued as normal. [4] If there is suspicion of toxicity, general supportive measures should be undertaken until clinical toxicity has decreased or resolved and then treatment may be continued. [4]

    Interactions

    Combined P-glycoprotein and strong or moderate CYP3A4 inducers such as rifampicin may decrease blood levels of darolutamide, while combined P-glycoprotein and strong CYP3A4 inhibitors such as itraconazole may increase blood levels of darolutamide. [4] Darolutamide is an inhibitor of the breast cancer resistance protein (BCRP) transporter and can increase blood levels of substrates for BCRP protein, such as rosuvastatin, by approximately 5-fold. [4]

    Pharmacology

    Pharmacodynamics

    Darolutamide is a second- or third-generation nonsteroidal antiandrogen (NSAA). [11] [12] It acts as a selective competitive silent antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). [4] Its affinity (Ki) for the AR is 11 nM and its functional inhibition (IC50 Tooltip half-maximal inhibitory concentration) of the AR is 26 nM. [10] The major metabolite of darolutamide, ketodarolutamide, has similar antiandrogenic activity relative to darolutamide (Ki = 8 nM; IC50 = 38 nM). [4] [10] In addition to its actions as an AR antagonist, darolutamide has been found to act as a silent antagonist of the progesterone receptor (PR), with approximately 1% of the potency of its AR antagonism. [4]

    A dosage of darolutamide of 1,200 mg/day has been found to result in a mean decrease in prostate specific antigen (PSA) levels of more than 90% in men with prostate cancer. [4] [ additional citation(s) needed ] The addition of darolutamide to castration has been found to decrease PSA levels by more than 50% in about 50% of men at 200 mg/day, 69% of men at 400 mg/day, 83% of men at 1,200 mg/day, and 86% of men at 1,400 mg/day. [22] [10] [7]

    Darolutamide shows some advantages in comparison to enzalutamide and apalutamide, two other second-generation NSAAs. [10] It appears to negligibly cross the blood–brain barrier, and hence has reduced risk of seizures and other central side effects from off-target GABAA receptor inhibition. [10] In accordance with its diminished central penetration, darolutamide does not appear to increase testosterone levels. [10] Darolutamide has been found to block the activity of all tested/well-known mutant ARs in prostate cancer, including the recently identified clinically-relevant F876L mutation that produces resistance to enzalutamide and apalutamide. [10] The medication shows higher affinity and inhibitory potency at the AR relative to enzalutamide and apalutamide in vitro (Ki = 11 nM relative to 86 nM for enzalutamide and 93 nM for apalutamide; IC50 Tooltip half-maximal inhibitory concentration = 26 nM relative to 219 nM for enzalutamide and 200 nM for apalutamide). [10]

    Darolutamide inhibits the organic anion transporting polypeptide (OATP) transporters OATP1B1 and OATP1B3 in vitro. [4] It shows no inhibition or induction of cytochrome P450 enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4) at clinically relevant concentrations. [23] Similarly, darolutamide shows no inhibition of a variety of other transporters (P-glycoprotein, MRP2, BSEP, OATs, OCTs, MATEs, OATP2B1, NTCP) at therapeutic concentrations. [4] [24]

    Pharmacokinetics

    Absorption

    The absolute bioavailability of darolutamide with oral administration of a single 300-mg dose without food is approximately 30%. [4] The bioavailability of darolutamide is increased by about 2- to 2.5-fold when administered with food, with a similar increase in exposure occurring for ketodarolutamide. [4] Exposure to darolutamide and ketodarolutamide increases in a nearly linear or dose-proportional manner across a dose range of 100 to 700 mg (or about 0.17- to 1.17-fold the recommended 600-mg dosage). [4] No further increase in exposure to darolutamide was observed at a dosage of darolutamide of 900 mg twice per day (or 1.5 times the recommended 600-mg dosage), indicating a saturation of absorption at doses above 700 mg. [4] Following a single 600-mg dose of darolutamide, peak levels of darolutamide occur after approximately 4 hours. [4] Steady-state levels of darolutamide occur after 2 to 5 days of continuous administration with food, during which time an approximate 2-fold accumulation in darolutamide levels occurs. [4] At steady state with 600 mg/day darolutamide, mean levels of darolutamide are 4.79 μg/mL and area-under-the-curve levels of darolutamide over time 0 to 12 hours (AUC0–12) are 52.82 h•μg/mL. [4] Total exposure to ketodarolutamide is approximately 1.7-fold that of darolutamide. [4]

    Distribution

    The volume of distribution of darolutamide with intravenous administration is 119 L. [4] The plasma protein binding of darolutamide is 92%, with 8% circulating freely, and of ketodarolutamide is 99.8%, with 0.2% circulating unbound. [4] As such, free levels of darolutamide in the circulation are about 40-fold higher than those of ketodarolutamide. [4] Both darolutamide and ketodarolutamide are bound mainly to albumin. [4] Darolutamide and ketodarolutamide appear to negligibly cross the blood–brain barrier both in mice and humans. [10] Darolutamide is a known substrate of P-glycoprotein and the breast cancer resistance protein (BCRP). [25] [26] [27] P-Glycoprotein is known to play a major role in excluding drugs from the brain due to efflux back across the blood–brain barrier. [28] [29]

    Metabolism

    Darolutamide is primarily metabolized into ketodarolutamide via dehydrogenation by CYP3A4 in the liver. [4] The medication is also conjugated via glucuronidation by UGT1A9 and UGT1A1. [4] The elimination half-life of darolutamide and ketodarolutamide has been reported to be approximately 20 hours. [4] A clinical study found that the elimination half-lives of darolutamide and ketodarolutamide at steady-state were 15.8 hours and 10.0 hours, respectively, with these half-lives being independent of dosage across a dose range of darolutamide of 200 to 1,800 mg/day. [7] The elimination half-life of darolutamide is far shorter than that of enzalutamide (e.g., 1.6 hours vs. 18.3 hours in mice). [10] The clearance of darolutamide following intravenous administration is 116 mL/min. [4]

    Excretion

    After a single oral dose of darolutamide, more than 95% of the dose is excreted in urine and feces within one week following administration. [4] A total of 63.4% darolutamide-related material is recovered in urine (about 7% as unchanged darolutamide) and a total of 32.4% darolutamide-related material (about 30% as unchanged darolutamide) is recovered in feces. [4]

    Variability

    No clinically significant differences in the pharmacokinetics of darolutamide have been observed in men with nmCRPC on the basis of age (48 to 95 years), race (white, Asian, black), mild-to-moderate renal impairment, or mild hepatic impairment. [4] In non-nmCRPC individuals with severe renal impairment not on dialysis, exposure to darolutamide was increased by about 2.5-fold relative to healthy people. [4] In non-nmCRPC individuals with moderate hepatic impairment, darolutamide exposure was increased by about 1.9-fold compared to healthy controls. [4] The pharmacokinetics of darolutamide have not been assessed in end-stage kidney disease or severe hepatic impairment. [4]

    Chemistry

    Darolutamide is a nonsteroidal compound and is structurally distinct from other marketed NSAAs, including enzalutamide and apalutamide. [10]

    History

    Darolutamide was developed by Orion Corporation and Bayer HealthCare. [30] Orion Corporation applied for a patent on darolutamide in October 2010, and this patent was published in May 2011. [13] Darolutamide entered phase I clinical trials in April 2011, [31] with the results of the first clinical study of darolutamide initially published in 2012. [32] The U.S. Food and Drug Administration (FDA) approved darolutamide in July 2019, under the agency's priority review designation. [8]

    Approval was based on ARAMIS, [33] a multicenter, double-blind, placebo-controlled clinical trial in 1,509 patients with non-metastatic castration resistant prostate cancer. Patients were randomized (2:1) to receive either 600 mg darolutamide orally twice daily (n=955) or matching placebo (n=554). All patients received a gonadotropin-releasing hormone (GnRH) analog concurrently or had a previous bilateral orchiectomy. Twelve patients with previous seizure histories were treated on the darolutamide arm. [8] [14]

    The primary endpoint was metastasis free survival (MFS), defined as the time from randomization to first evidence of distant metastasis or death from any cause within 33 weeks after the last evaluable scan, whichever occurred first. The median MFS was 40.4 months (95% CI: 34.3, not reached) for patients treated with darolutamide compared with 18.4 months (95% CI: 15.5, 22.3) for those receiving placebo (hazard ratio 0.41; 95% CI: 0.34, 0.50; p<0.0001).

    Darolutamide was associated with greater benefits than placebo for all secondary end points, including overall survival (hazard ratio 0.69; 95% CI: 0.53-0.88; P=0.003), time to pain progression (median 40.3 months vs. 25.4 months; hazard ratio 0.65; 95% CI: 0.53-0.79; P<0.001), time to cytotoxic chemotherapy (hazard ratio 0.43; 95% CI: 0.31-0.60), and time to a symptomatic skeletal event (hazard ratio 0.43; 95% CI: 0.22-0.84). [33]

    Society and culture

    Generic names

    Darolutamide is the generic name of the medication and its INN Tooltip International Nonproprietary Name and USAN Tooltip United States Adopted Name. [34] It is also known by its developmental code names ODM-201 and BAY-1841788. [30]

    Brand names

    Darolutamide is marketed under the brand name Nubeqa. [4] [8] [5]

    Availability

    Darolutamide is available in the United States and the European Union. [4] [8] [5] [35]

    Research

    Darolutamide monotherapy is being studied in comparison to androgen deprivation therapy with GnRH agonist or antagonist monotherapy in men with treatment-naive prostate cancer. [22] [36] As of 2018, it is entering a phase II clinical trial for this indication. [22] [36] This study is expected for completion in 2021 or 2022. [37]

    Darolutamide is being studied for the treatment of breast cancer in women. [30] As of November 2019, it is in phase II clinical trials for this indication. [30]

    Related Research Articles

    <span class="mw-page-title-main">Bicalutamide</span> Prostate cancer treatment

    Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC). To a lesser extent, it is used at high doses for locally advanced prostate cancer (LAPC) as a monotherapy without castration. Bicalutamide was also previously used as monotherapy to treat localized prostate cancer (LPC), but authorization for this use was withdrawn following unfavorable trial findings. Besides prostate cancer, bicalutamide is limitedly used in the treatment of excessive hair growth and scalp hair loss in women, as a puberty blocker and component of feminizing hormone therapy for transgender girls and women, to treat gonadotropin-independent early puberty in boys, and to prevent overly long-lasting erections in men. It is taken by mouth.

    <span class="mw-page-title-main">Nilutamide</span> Chemical compound

    Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer. It has also been studied as a component of feminizing hormone therapy for transgender women and to treat acne and seborrhea in women. It is taken by mouth.

    <span class="mw-page-title-main">Abiraterone acetate</span> Chemical compound

    Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It should either be used following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is taken by mouth.

    <span class="mw-page-title-main">Enzalutamide</span> Antiandrogen medication used in treatment of prostate cancer

    Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

    <span class="mw-page-title-main">Cabazitaxel</span> Chemical compound

    Cabazitaxel, sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

    <span class="mw-page-title-main">Galeterone</span> Chemical compound

    Galeterone is a steroidal antiandrogen which was under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique triple mechanism of action, acting as an androgen receptor antagonist, androgen receptor down regulator, and CYP17A1 inhibitor, the latter of which prevents the biosynthesis of androgens. As a CYP17A1 inhibitor, galeterone shows selectivity for 17,20-lyase over 17α-hydroxylase.

    <span class="mw-page-title-main">Tasquinimod</span> Chemical compound

    Tasquinimod is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy. Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the immune system. It is now in phase III development, following successful phase II trial outcomes.

    PROSTVAC is a cancer immunotherapy candidate in clinical development by Bavarian Nordic for the treatment of all prostate cancer although clinical trials are focusing on more advanced cases of metastatic castration-resistant prostate cancer (mCRPC). PROSTVAC is a vaccine designed to enable the immune system to recognize and attack prostate cancer cells by triggering a specific and targeted T cell immune response to cancer cells that express the tumor-associated antigen prostate-specific antigen (PSA).

    <span class="mw-page-title-main">Nonsteroidal antiandrogen</span> Antiandrogen with a nonsteroidal chemical structure

    A nonsteroidal antiandrogen (NSAA) is an antiandrogen with a nonsteroidal chemical structure. They are typically selective and full or silent antagonists of the androgen receptor (AR) and act by directly blocking the effects of androgens like testosterone and dihydrotestosterone (DHT). NSAAs are used in the treatment of androgen-dependent conditions in men and women. They are the converse of steroidal antiandrogens (SAAs), which are antiandrogens that are steroids and are structurally related to testosterone.

    <span class="mw-page-title-main">Seviteronel</span> Chemical compound

    Seviteronel is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body. As of July 2017, seviteronel is in phase II clinical trials for both prostate cancer and breast cancer. In January 2016, it was designated fast-track status by the United States Food and Drug Administration for prostate cancer. In April 2017, seviteronel received fast-track designation for breast cancer as well.

    <span class="mw-page-title-main">Apalutamide</span> Chemical compound

    Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC). It is taken by mouth.

    <span class="mw-page-title-main">Ralaniten acetate</span> Chemical compound

    Ralaniten acetate is a first-in-class antiandrogen that targets the N-terminal domain (NTD) of the androgen receptor (AR) developed by ESSA Pharmaceuticals and was under investigation for the treatment of prostate cancer. This mechanism of action is believed to allow the drug to block signaling from the AR and its splice variants. EPI-506 is a derivative of bisphenol A and a prodrug of ralaniten (EPI-002), one of the four stereoisomers of EPI-001, and was developed as a successor of EPI-001. The drug reached phase I/II prior to the discontinuation of its development. It showed signs of efficacy in the form of prostatic specific antigen (PSA) decreases (4–29%) predominantly at higher doses (≥1,280 mg) in some patients but also caused side effects and was discontinued by its developer in favor of next-generation AR NTD inhibitors with improved potency and tolerability.

    <span class="mw-page-title-main">Proxalutamide</span> Chemical compound

    Proxalutamide is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer. It was approved in Paraguay for the treatment of COVID-19 in July 2021, but has not been approved at this time in other countries.

    Ketodarolutamide is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of darolutamide, an NSAA which is used in the treatment of prostate cancer in men. Similarly to its parent compound, ketodarolutamide acts as a highly selective, high-affinity, competitive silent antagonist of the androgen receptor (AR). Both agents show much higher affinity and more potent inhibition of the AR relative to the other NSAAs enzalutamide and apalutamide, although they also possess much shorter and comparatively less favorable elimination half-lives. They have also been found not to activate certain mutant AR variants that enzalutamide and apalutamide do activate. Both darolutamide and ketodarolutamide show limited central nervous system distribution, indicating peripheral selectivity, and little or no inhibition or induction of cytochrome P450 enzymes such as CYP3A4, unlike enzalutamide and apalutamide.

    <i>N</i>-Desmethylenzalutamide Chemical compound

    N-Desmethylenzalutamide is a nonsteroidal antiandrogen (NSAA) and the major metabolite of enzalutamide, an NSAA which is used as a hormonal antineoplastic agent in the treatment of metastatic prostate cancer. It has similar activity to that of enzalutamide and, with enzalutamide therapy, circulates at similar concentrations to those of enzalutamide at steady state. N-Desmethylenzalutamide is formed from enzalutamide in the liver by the cytochrome P450 enzymes CYP2C8 and CYP3A4. It has a longer terminal half-life than enzalutamide.

    The side effects of bicalutamide, a nonsteroidal antiandrogen (NSAA), including its frequent and rare side effects, have been well-studied and characterized. The most common side effects of bicalutamide monotherapy in men include breast tenderness, breast growth, feminization, demasculinization, and hot flashes. Less common side effects of bicalutamide monotherapy in men include sexual dysfunction, depression, fatigue, weakness, and anemia. Bicalutamide is well tolerated and has few side effects in women. General side effects of bicalutamide that may occur in either sex include diarrhea, constipation, abdominal pain, nausea, dry skin, itching, and rash.

    Comparison of the nonsteroidal antiandrogen (NSAA) bicalutamide with other antiandrogens reveals differences between the medications in terms of efficacy, tolerability, safety, and other parameters. Relative to the other first-generation NSAAs, flutamide and nilutamide, bicalutamide shows improved potency, efficacy, tolerability, and safety, and has largely replaced these medications in clinical practice. Compared to the second-generation NSAAs, enzalutamide and apalutamide, bicalutamide has inferior potency and efficacy but similar tolerability and safety and a lower propensity for drug interactions.

    <span class="mw-page-title-main">Pharmacology of bicalutamide</span>

    The pharmacology of bicalutamide is the study of the pharmacodynamic and pharmacokinetic properties of the nonsteroidal antiandrogen (NSAA) bicalutamide. In terms of pharmacodynamics, bicalutamide acts as a selective antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has no capacity to activate the AR. It does not decrease androgen levels and has no other important hormonal activity. The medication has progonadotropic effects due to its AR antagonist activity and can increase androgen, estrogen, and neurosteroid production and levels. This results in a variety of differences of bicalutamide monotherapy compared to surgical and medical castration, such as indirect estrogenic effects and associated benefits like preservation of sexual function and drawbacks like gynecomastia. Bicalutamide can paradoxically stimulate late-stage prostate cancer due to accumulated mutations in the cancer. When used as a monotherapy, bicalutamide can induce breast development in males due to its estrogenic effects. Unlike other kinds of antiandrogens, it may have less adverse effect on the testes and fertility.

    <span class="mw-page-title-main">RD-162</span> Chemical compound

    RD-162 is a second-generation nonsteroidal antiandrogen (NSAA) which was developed for the treatment of prostate cancer but was never marketed. It acts as a potent and selective silent antagonist of the androgen receptor (AR). The drug is a diarylthiohydantoin derivative. It is closely related to enzalutamide and apalutamide. Both RD-162 and enzalutamide show 5- to 8-fold higher affinity for the AR than the first-generation NSAA bicalutamide, and only 2- to 3-fold lower affinity than dihydrotestosterone (DHT), the major endogenous ligand of the receptor in the prostate gland.

    <span class="mw-page-title-main">Rezvilutamide</span> Chemical compound

    Rezvilutamide, sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer. It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide. The drug was developed by Jiangsu Hengrui Medicine. Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.

    References

    1. ↑ "Nubeqa Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 4 March 2020. Retrieved 16 August 2020.
    2. ↑ "Product Monograph" (PDF). hres.ca. Retrieved 25 October 2023.
    3. ↑ "Summary Basis of Decision (SBD) for Nubeqa". Health Canada. 23 October 2014. Retrieved 29 May 2022.
    4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 "Nubeqa- darolutamide tablet, film coated". DailyMed . 31 July 2019. Retrieved 22 November 2019.
    5. 1 2 3 4 5 "Nubeqa EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 16 August 2020.
    6. ↑ "Nubeqa Product information". Union Register of medicinal products. Retrieved 3 March 2023.
    7. 1 2 3 4 5 Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. (August 2014). "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial" (PDF). The Lancet. Oncology. 15 (9): 975–85. doi:10.1016/S1470-2045(14)70240-2. PMID   24974051.
    8. 1 2 3 4 5 6 PD-icon.svg This article incorporates text from this source, which is in the public domain : "FDA approves darolutamide for non-metastatic castration-resistant prostate cancer". U.S. Food and Drug Administration (FDA) (Press release). 31 July 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019.
    9. 1 2 3 Fizazi K, Albiges L, Loriot Y, Massard C (2015). "ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer". Expert Review of Anticancer Therapy. 15 (9): 1007–17. doi:10.1586/14737140.2015.1081566. PMC   4673554 . PMID   26313416.
    10. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. (July 2015). "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies". Scientific Reports. 5: 12007. Bibcode:2015NatSR...512007M. doi:10.1038/srep12007. PMC   4490394 . PMID   26137992.
    11. 1 2 Shore ND (June 2017). "Darolutamide (ODM-201) for the treatment of prostate cancer". Expert Opinion on Pharmacotherapy. 18 (9): 945–952. doi:10.1080/14656566.2017.1329820. PMID   28490267. S2CID   20624649.
    12. 1 2 Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, et al. (November 2018). "Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens". The Journal of Urology. 200 (5): 956–966. doi:10.1016/j.juro.2018.04.083. PMID   29730201. S2CID   19162538.
    13. 1 2 "Androgen receptor modulating compounds".
    14. 1 2 PD-icon.svg This article incorporates text from this source, which is in the public domain : "Drug Trials Snapshots: Nubeqa". U.S. Food and Drug Administration (FDA). 9 August 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019.
    15. ↑ "AusPAR: Darolutamide". Therapeutic Goods Administration (TGA). 3 August 2020. Retrieved 22 September 2020.
    16. ↑ Hird AE, Magee DE, Bhindi B, Ye XY, Chandrasekar T, Goldberg H, Klotz L, Fleshner N, Satkunasivam R, Klaassen Z, Wallis CJ (October 2020). "A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer". Clin Genitourin Cancer. 18 (5): 343–350. doi:10.1016/j.clgc.2020.02.005. PMID   32278840. S2CID   215748376.
    17. ↑ Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF (November 2020). "Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis". Int J Clin Oncol. 25 (11): 1892–1900. doi:10.1007/s10147-020-01777-9. PMC   7572325 . PMID   32924096.
    18. ↑ Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N (August 2021). "Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer". The Journal of Urology. 206 (2): 298–307. doi: 10.1097/JU.0000000000001767 . PMID   33818140.
    19. 1 2 Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, et al. (May 2021). "Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis". Prostate Cancer and Prostatic Diseases. 25 (2): 139–148. doi: 10.1038/s41391-021-00395-4 . PMC   9184262 . PMID   34054128.
    20. ↑ Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J (September 2014). "New agents for prostate cancer". Annals of Oncology. 25 (9): 1700–9. doi: 10.1093/annonc/mdu038 . PMID   24658665.
    21. ↑ Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". BJU International. 91 (5): 455–61. doi: 10.1046/j.1464-410x.2003.04026.x . PMID   12603397. S2CID   8639102.
    22. 1 2 3 Fizazi K, Smith MR, Tombal B (October 2018). "Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer". Clinical Genitourinary Cancer. 16 (5): 332–340. doi: 10.1016/j.clgc.2018.07.017 . PMID   30197098.
    23. ↑ Sternberg CN, Petrylak DP, Madan RA, Parker C (2014). "Progress in the treatment of advanced prostate cancer". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting (34): 117–31. doi: 10.14694/EdBook_AM.2014.34.117 . PMID   24857068.
    24. ↑ Zurth C, Graudenz K, Denner K, Korjamo T, Fricke R, Wilkinson G, Seitz F, Prien O (2019). "Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies". Journal of Clinical Oncology. 37 (7_suppl): 297. doi:10.1200/JCO.2019.37.7_suppl.297. ISSN   0732-183X. S2CID   87513637.
    25. ↑ Palmieri VE, Roviello G, D'Angelo A, Casadei C, De Giorgi U, Giorgione R (May 2021). "Darolutamide in hormone-sensitive and castration-resistant prostate cancer". Expert Rev Clin Pharmacol. 14 (5): 535–544. doi:10.1080/17512433.2021.1901580. PMID   33685318. S2CID   232159762.
    26. ↑ Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, Denner K, Bairlein M, von Bühler CJ, Wilkinson G, Gieschen H (December 2019). "Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies". Eur J Drug Metab Pharmacokinet. 44 (6): 747–759. doi:10.1007/s13318-019-00577-5. PMC   6828636 . PMID   31571146.
    27. ↑ Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K (October 2019). "Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial". Target Oncol. 14 (5): 527–539. doi:10.1007/s11523-019-00674-0. PMC   6797643 . PMID   31571095.
    28. ↑ Schinkel AH (April 1999). "P-Glycoprotein, a gatekeeper in the blood-brain barrier". Adv Drug Deliv Rev. 36 (2–3): 179–194. doi:10.1016/s0169-409x(98)00085-4. PMID   10837715.
    29. ↑ Fromm MF (February 2000). "P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs". Int J Clin Pharmacol Ther. 38 (2): 69–74. doi:10.5414/cpp38069. PMID   10706193.
    30. 1 2 3 4 "Darolutamide - Bayer HealthCare/Orion". Adis Insight. Springer Nature Switzerland AG.
    31. ↑ James L. Gulley (20 December 2011). Prostate Cancer. Demos Medical Publishing. pp. 513–. ISBN   978-1-936287-46-8.
    32. ↑ Leibowitz-Amit R, Joshua AM (December 2012). "Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions". Current Oncology. 19 (Suppl 3): S22-31. doi: 10.3747/co.19.1281 . PMC   3553559 . PMID   23355790.
    33. 1 2 Clinical trial number NCT02200614 for "Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer (ARAMIS)" at ClinicalTrials.gov
    34. ↑ "Darolutamide". ChemIDplus. U.S. National Library of Medicine.
    35. ↑ Chustecka Z (31 January 2020). "Darolutamide (Nubeqa) Gets OK in Europe for Prostate Cancer". MedScape.
    36. 1 2 Tombal BF, Gillessen S, Loriot Y, Marreaud S, Collette L, Saad F (2018). "Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa)". Journal of Clinical Oncology. 36 (6_suppl): TPS406. doi:10.1200/JCO.2018.36.6_suppl.TPS406. ISSN   0732-183X.
    37. ↑ "ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer". ClinicalTrials.gov. 23 November 2016. Retrieved 16 August 2020.
    This page is based on this Wikipedia article
    Text is available under the CC BY-SA 4.0 license; additional terms may apply.
    Images, videos and audio are available under their respective licenses.